Our findings also show that functional p53 tumor suppressor activity is a requirement for selinexor single-agent activity in AML and that combination therapy with the MDM2 inhibitor nutlin-3a leads to elevated p53 levels and synergistic cell killing. Here, MDM2 is linked to acute myeloid leukemia.